Tafolecimab (PCSK9) - Onderzoeksklasse Biosimilar
Gecertificeerd

Tafolecimab (PCSK9) - Onderzoeksklasse Biosimilar

Catalog #: 11-001
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

GPRC5D / CD3 bispecific antibody is used to treat multiple myeloma. The bispecific antibody is commonly known as tafolecimab. It is constructed using the Duobody technology authorized by Genmab. The heavy chain of anti-CD3 antibody introduced F405L and R409K to construct the double antibody. S228P, F234A, and L235A mutations were simultaneously introduced into the IgG4 constant region.

Immunogen

Homo sapiens / PCSK9 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Neuroscience

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG2-kappa

NCBI Organism

Homo sapiens

Other Product Names

IBI-306

Beschrijving

Tafolecimab (PCSK9) - Onderzoeksklasse Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamTafolecimab (PCSK9) - Onderzoeksklasse Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer11-001